Serum Level of Macrophage Migration Inhibitory Factor (MIF) in Egyptians with Alopecia Areata and Its Relation to the Clinical Severity of the Disease

Overview

Journal J Clin Lab Anal

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
Pathology

Date 2014 Apr 2

PMID 24687398

Citations 5

Authors

Doreen Nazeih Assaad Younan

Naglaa Agamia

Adel Elshafei

Nancy Ebeid

Affiliations

Soon will be listed here.

Abstract

Background: Alopecia areata (AA) is a common dermatological problem that manifests as sudden loss of hair without any inflammation or scarring. Various cytokines are implicated in the pathogenesis of this disease. Macrophage migration inhibitory factor (MIF) is located at an upstream position in the events leading to the possible dysregulated immuno-inflammatory responses, and the high level of this cytokine in AA may suggest a role of MIF in the pathogenesis of AA.

Methods: This case-control study was carried out on 31 AA patients with different grades of severity and 15 apparently healthy subjects. Serum MIF level was measured by ELISA, and was correlated with the clinical severity of the disease using SALT (severity of alopecia tool) scoring system.

Results: In this study, there was a significant elevation in serum MIF levels in AA patients in comparison with controls. There was also a positive correlation between MIF levels and clinical severity and disease duration.

Conclusion: MIF seems to have an essential role in the etiopathogenesis of AA. So, it is considered to be a promising target in the therapy of autoimmune diseases and as a future predictor of alopecia activity. Anti-MIF therapy might be added as one of the new biological treatments for AA.

Citing Articles

Alopecia Areata: A Review of the Genetic Variants and Immunodeficiency Disorders Associated with Alopecia Areata.

Englander H, Paiewonsky B, Castelo-Soccio L Skin Appendage Disord. 2023; 9(5):325-332.

PMID: 37900769 PMC: 10601931. DOI: 10.1159/000530432.

The Immunogenetics of Alopecia areata.

Rajabi F, Abdollahimajd F, Jabalameli N, Kashani M, Firooz A Adv Exp Med Biol. 2022; 1367:19-59.

PMID: 35286691 DOI: 10.1007/978-3-030-92616-8_2.

Macrophage Migration Inhibitory Factor in Alopecia Areata and Vitiligo: A Case-Controlled Serological Study.

Eldesouky F, Ibrahim A, Sharaf S J Clin Aesthet Dermatol. 2021; 13(10):24-27.

PMID: 33584953 PMC: 7840085.

Tumor necrosis factor (TNF)-α- 308 G/A gene polymorphism (rs1800629) in Egyptian patients with alopecia areata and vitiligo, a laboratory and in silico analysis.

Abd El-Raheem T, Mahmoud R, Hefzy E, Masoud M, Ismail R, Aboraia N PLoS One. 2020; 15(12):e0240221.

PMID: 33370782 PMC: 7769607. DOI: 10.1371/journal.pone.0240221.

Migration Inhibitory Factor in Conditioned Medium from Human Umbilical Cord Blood-Derived Mesenchymal Stromal Cells Stimulates Hair Growth.

Oh H, Kwak J, Kim B, Jin H, Park W, Choi S Cells. 2020; 9(6).

PMID: 32481584 PMC: 7349163. DOI: 10.3390/cells9061344.

References

Namazi M, Fallahzadeh M, Shaghelani H, Kamali-Sarvestani E . Marked elevation of serum macrophage migration inhibitory factor levels in patients with pemphigus vulgaris. Int J Dermatol. 2009; 49(2):146-8. DOI: 10.1111/j.1365-4632.2009.04238.x. View

Shimizu T, Mizue Y, Abe R, Watanabe H, Shimizu H . Increased macrophage migration inhibitory factor (MIF) in the sera of patients with extensive alopecia areata. J Invest Dermatol. 2002; 118(3):555-7. DOI: 10.1046/j.0022-202x.2001.01669.x. View

Lolis E, Bucala R . Macrophage migration inhibitory factor. Expert Opin Ther Targets. 2003; 7(2):153-64. DOI: 10.1517/14728222.7.2.153. View

Teraki Y, Imanishi K, Shiohara T . Cytokines in alopecia areata: contrasting cytokine profiles in localized form and extensive form (alopecia universalis). Acta Derm Venereol. 1996; 76(6):421-3. DOI: 10.2340/0001555576421423. View

Martinez-Mir A, Zlotogorski A, Gordon D, Petukhova L, Mo J, Gilliam T . Genomewide scan for linkage reveals evidence of several susceptibility loci for alopecia areata. Am J Hum Genet. 2007; 80(2):316-28. PMC: 1785354. DOI: 10.1086/511442. View

Shimizu T, Hizawa N, Honda A, Zhao Y, Abe R, Watanabe H . Promoter region polymorphism of macrophage migration inhibitory factor is strong risk factor for young onset of extensive alopecia areata. Genes Immun. 2005; 6(4):285-9. DOI: 10.1038/sj.gene.6364191. View

Rodriguez T, Duvic M . Onset of alopecia areata after Epstein-Barr virus infectious mononucleosis. J Am Acad Dermatol. 2008; 59(1):137-9. DOI: 10.1016/j.jaad.2008.02.005. View

Stosic-Grujicic S, Stojanovic I, Maksimovic-Ivanic D, Momcilovic M, Popadic D, Harhaji L . Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus. J Cell Physiol. 2007; 215(3):665-75. DOI: 10.1002/jcp.21346. View

Bodemer C, Peuchmaur M, Fraitaig S, Chatenoud L, Brousse N, de Prost Y . Role of cytotoxic T cells in chronic alopecia areata. J Invest Dermatol. 2000; 114(1):112-6. DOI: 10.1046/j.1523-1747.2000.00828.x. View

10.

Aloisi A, Pari G, Ceccarelli I, Vecchi I, Ietta F, Lodi L . Gender-related effects of chronic non-malignant pain and opioid therapy on plasma levels of macrophage migration inhibitory factor (MIF). Pain. 2005; 115(1-2):142-51. DOI: 10.1016/j.pain.2005.02.019. View

11.

Hoffmann R . The potential role of cytokines and T cells in alopecia areata. J Investig Dermatol Symp Proc. 2000; 4(3):235-8. DOI: 10.1038/sj.jidsp.5640218. View

12.

Repp A, Mayhew E, Apte S, Niederkorn J . Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J Immunol. 2000; 165(2):710-5. DOI: 10.4049/jimmunol.165.2.710. View

13.

Nishihira J, Mitsuyama K . Overview of the role of macrophage migration inhibitory factor (MIF) in inflammatory bowel disease. Curr Pharm Des. 2009; 15(18):2104-9. DOI: 10.2174/138161209788489113. View

14.

Shimizu T, Abe R, Ohkawara A, Nishihira J . Ultraviolet B radiation upregulates the production of macrophage migration inhibitory factor (MIF) in human epidermal keratinocytes. J Invest Dermatol. 1999; 112(2):210-5. DOI: 10.1046/j.1523-1747.1999.00486.x. View

15.

Serarslan G, Yonden Z, Sogut S, Savas N, Celik E, Arpaci A . Macrophage migration inhibitory factor in patients with vitiligo and relationship between duration and clinical type of disease. Clin Exp Dermatol. 2009; 35(5):487-90. DOI: 10.1111/j.1365-2230.2009.03617.x. View

16.

Stosic-Grujicic S, Stojanovic I, Nicoletti F . MIF in autoimmunity and novel therapeutic approaches. Autoimmun Rev. 2008; 8(3):244-9. DOI: 10.1016/j.autrev.2008.07.037. View

17.

Hoi A, Hickey M, Hall P, Yamana J, OSullivan K, Santos L . Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice. J Immunol. 2006; 177(8):5687-96. DOI: 10.4049/jimmunol.177.8.5687. View

18.

Shimizu T . Role of macrophage migration inhibitory factor (MIF) in the skin. J Dermatol Sci. 2005; 37(2):65-73. DOI: 10.1016/j.jdermsci.2004.08.007. View

19.

Shimizu T, Abe R, Nakamura H, Ohkawara A, Suzuki M, Nishihira J . High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Commun. 1999; 264(3):751-8. DOI: 10.1006/bbrc.1999.1584. View

20.

Foote A, Briganti E, Kipen Y, Santos L, Leech M, Morand E . Macrophage migration inhibitory factor in systemic lupus erythematosus. J Rheumatol. 2004; 31(2):268-73. View